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Short Report
Challenges and solutions to nicotine
replacement therapy access: observations
from SCIMITAR+
Catherine E. Arundel, Emily Peckham, Della Bailey, Suzanne Crosland, Paul Heron and Simon Gilbody
Background
Given that smoking results in poor physical and mental health,
reducing tobacco harm is of high importance.
Recommendations published by the National Institute for Health
and Care Excellence to reduce smoking harms included provi-
sion of support, use of nicotine containing products and com-
missioning of smoking cessation services.
Aims
This report explores the difficulties in obtaining such support, as
observed in a recently conducted randomised controlled trial in
patientswith severemental ill health, and outlines suggestions to
improve facilitation of provision.
Method
Data collected during the Smoking Cessation Intervention for
Severe Mental Ill Health Trial (SCIMITAR+) (trial Registration
ISRCTN72955454), was reviewed to identify the difficulties
experienced, across the trial, with regards to access and provi-
sion of nicotine replacements therapy (NRT). Actions taken to
facilitate access and provision of NRT were collated to outline
how provision could be better facilitated.
Results
Access to NRT varied across study settings and in some
instances proved impossible for patients to access. Difficulty in
access was irrespective of a diagnosis of severemental ill health.
Where NRT was provided, this was not always provided in
accordance with NICE guidelines.
Conclusions
Availability of smoking cessation support, and NRT provision
would benefit from being made clearer, simpler and more easily
accessible so as to enhance smoking cessation rates.
Keywords
Smoking cessation; nicotine replacement therapy; smoking
cessation services; severe mental ill health; barriers and
facilitators.
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Background
Figures suggest that 57–68 % of people with severe mental ill health
(SMI) smoke tobacco compared with 19 % in the general popula-
tion,1,2 resulting in an average loss of 17 years of life on account
of smoking.2Reducing tobacco harm in people with SMI is therefore
of high importance.
The National Institute for Health and Care Excellence (NICE)
guidance (PH48),3 focused on reducing smoking harms in second-
ary care and mental health settings through provision of support,
use of nicotine containing products and commissioning of
smoking cessation services. Both NICE PH483 and guidance from
the Royal College of General Practitioners and Royal College of
Psychiatrists4 propose that people with SMI should be offered
behavioural support, in addition to two forms of nicotine replace-
ment therapy (NRT), given that this increases the odds of
smoking cessation with little adverse effect.3–5
Despite this guidance, smoking cessation service spending
reduced by £41 million between 2014/2015 and 2017/2018,6 and a
75 % reduction in prescribed smoking cessation products has been
identified.7Given the impact smoking has on overall health and that
this is the single most modifiable risk factor for early death, this is of
significant concern.
Aims
The recent Smoking Cessation Intervention for Severe Mental Ill
Health Trial (SCIMITAR+, trial registration: ISRCTN72955454),8
recruited participants between 7 October 2015 and 16 December
2016 to evaluate the effectiveness of a bespoke smoking cessation
intervention using tailored support compared with regular smoking
cessation provision for people with SMI.8 As part of the intervention,
participants were encouraged to use two forms ofNRT, in accordance
with those recommendations as detailed above.3,4
During the trial,8 access to NRT varied across study settings and
in some instances proved impossible for patients to obtain. This
brief report describes the differences and difficulties in NRT
access, in the context of people with SMI, and aims to identify
how NRT access could be better facilitated, both for those with
SMI and also in the general population.
Method
Data collected during SCIMITAR+, was reviewed to identify the dif-
ficulties experienced, across the trial with regards to access and pro-
vision of NRT. Actions taken to facilitate access and provision of
NRT were collated.
Ethical approval and consent to participate
The authors assert that all procedures contributing to this work
comply with the ethical standards of the relevant national and insti-
tutional committees on human experimentation and with the
Helsinki Declaration of 1975, as revised in 2008. This work was con-
ducted as part of SCIMITAR+ for which ethical approval was
obtained: NRES Committee Yorkshire and The Humber – Leeds
East Research Ethics Committee on 19 March 2015 (ref: 15/YH/
0051261). SCIMITAR+ obtained written informed consent from
all participants.
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Results
There were a number of barriers to NRT access.
Barriers to NRT access
Initially in SCIMITAR+, smoking cessation services were provided
by general practitioner (GP) practices. As the study progressed,
smoking cessation provision diversified with provision being sup-
plied by GP practices, the local government Stop Smoking
Services, charitable Stop Smoking Services and hospitals, either
independently or in collaboration with other groups. While NRT
is available to purchase, for low income groups cost was a barrier
and so NRT was usually provided at a lower cost directly by the
local service providing smoking cessation support, or via the GP
through prescription.
In some areas of the UK, NRT prescribing had been devolved
from GP practices to the local Stop Smoking Services run by the
local government or charities. Where this had occurred, the
change was not always clearly publicised and so it was often difficult
to identify who was responsible for local prescribing. Having to
navigate complicated local arrangements to obtain support, and
NRT, has the potential to disincentivise patients from pursuing a
smoking cessation attempt.
Where GP practices remained responsible for NRT prescribing,
rarely were prescription requests rejected. Where these were
rejected, this was especially pertinent where patients had expressed
an interest in using alternative evidence-based pharmacological
treatments (for example varenicline) as some GPs deemed that
these products were not appropriate for use in patients with SMI.
This is likely the result of earlier reports9 that suggested use of
these medications may increase psychiatric symptoms or events in
patients with SMI, however, this has subsequently been refuted.10
In some cases, prescribing by the mental health team was required
to facilitate patient access to NRT; however, this was not a sustain-
able alternative to a GP prescribing in the long term.
Where funding for smoking cessation services was devolved to
local government, but was not protected, this resulted in a reduction
in smoking cessation services, which were only available to specific
patient groups for example, pregnant women and patients with
respiratory disorders.
Where access was available, the levels of prescribing were
restricted either to one type of NRT or for a defined period of pre-
scribing only, largely because of services trying to preserve limited
available funding. This contravenes the recommendations made
both in terms of prescribing quantity and duration4 and may
result in patients being either disincentivised to, or to be able to
sustain a quit attempt.
Increasing prescription costs were also identified as a barrier
for some patients, particularly those who were not in receipt of
prescription fee exemption (for example those not in receipt of
welfare benefit). The most significant impact of this was on
initial prescribing ahead of smoking cessation or on patients
cutting down prior to making a quit attempt (cutting down to
quit). As the patient decreased or ceased their cigarette use,
the savings made will likely have off-set this financial burden
to some degree.
Discussion
Despite the recommendations made in both NICE and UK Primary
Care Guidance documents,3,4 SCIMITAR+ identified distinct vari-
ability in provision of NRT for patients wishing to quit smoking.
Implications
Given the impact smoking has on overall health and that this is the
single most modifiable risk factor for early death, reversing the
decline in access is imperative to ensure patients with a current
history of smoking are given sufficient resources to make, and to
sustain, a quit attempt. In line with previous guidance,3,4 it is sug-
gested that resource is reviewed and increased, so as to facilitate
ease of access to relevant support services and medications.
Education among healthcare practitioners is also important to
dispel misconceptions regarding use of smoking cessation medica-
tion and to increase awareness of clinical prescribing guidelines.
Within SCIMITAR+, it was possible to remove or reduce some
of the barriers through provision of centralised support to enable
access to NRT, coordinated and delivered by a member of the
trial team. This contact enabled misconceptions regarding NRT
use or smoking cessation in this population to be tackled and con-
cerns to be allayed, and resolution methods identified and imple-
mented on a case by case basis.
As a result, a single, centralised contact with services providing
NRT may be useful to facilitate education around and coordination
of NRT provision in a standardised manner across the UK. Where
the responsibility of smoking cessation provision has been devolved
to local governments, it is also suggested that funding is protected to
enable appropriate provision to be provided to those who require
access to support and NRT provision.
In the context of further research in relation to smoking cessation,
it is suggested that study teams should consider, from the outset, how
best to facilitate NRT provision from smoking cessation services. It
may be relevant to obtain approvals to provide NRT within the trial
setting; however, thismay limit the transferability of effective strategies
into routine practice, if NRT access continues to be restricted and/or is
difficult. Where NRT is to be provided through routine prescribing, it
is suggested that study teams consider implementing a centralised
point of support within the trial team to facilitate this.
In conclusion, evaluation of activity and experiences observed in
the conduct of SCIMITAR+ has identified that NRT is routinely dif-
ficult for patients to access. Where access is available, decommis-
sioning or service cuts mean that two forms of NRT are not
always provided, and provision of products is for a fixed-time
period only. Availability of smoking cessation support, and NRT
provision would benefit from being made clearer, simpler and
more easily accessible so as to enhance smoking cessation rates.
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